KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial. PMID 42364816 · Radiother Oncol · 2026-Jun-27 干预为非药物单独策略,未满足药物干预要求。
H B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
JAAD Game Changers: "Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial". PMID 42364776 · J Am Acad Dermatol · 2026-Jun-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial. PMID 42363777 · Int J Cancer · 2026-Jun-27 The record does not meet all eligibility criteria: while it is an oncology-related, human, randomized trial with a time-to-event endpoint and original results, it lacks a drug-containing intervention and explicit Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. PMID 42330995 · Lancet · 2026-Jun-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trial. PMID 42363252 · Int J Retina Vitreous · 2026-Jun-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immersive virtual reality with synchronous neurostimulation for upper-limb recovery after stroke: a randomized feasibility trial. PMID 42362865 · Nat Med · 2026-Jun-26 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Beyond the "cold" barrier: Redefining the clinical paradigm of immune checkpoint inhibitor therapy in ovarian cancer. PMID 42362076 · Crit Rev Oncol Hematol · 2026-Jun-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial. PMID 42361317 · Eur J Heart Fail · 2026-Jun-26 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial. PMID 42361276 · J Clin Oncol · 2026-Jun-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial. PMID 42360803 · Clin Cancer Res · 2026-Jun-26 This is a pre-specified biomarker subgroup analysis of the ENZAMET trial, not the primary result report of the randomized Phase III trial itself. The primary trial results are reported elsewhere.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Global Trends in Surgical Oncology Deescalation Phase III Randomized Trials. PMID 42360646 · Ann Surg Oncol · 2026-Jun-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study. PMID 42360473 · J Neurol · 2026-Jun-26 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. PMID 42360104 · Clin Cancer Res · 2026-Jun-26 The record reports a secondary analysis (identifying variables associated with early detriment) from two Phase III randomized trials (CheckMate 227 and 9LA). While the underlying trials are eligible, this specific publication is not a primary report of an original efficacy endpoint. The abstract focuses on rapid progression rates and biomarker associations, not on presenting Kaplan-Meier survival curves or hazard ratios for the primary trial endpoints. Therefore, it does not meet the criterion of being an original formal-result report with a primary/key secondary time-to-event efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-led, home-based follow-up for colorectal cancer: the DISTANCE multicentre stepped-wedge cluster-randomised trial. PMID 42359543 · Br J Surg · 2026-Jun-26 The record is an oncology, human, randomized trial with results, but it is excluded because it is not a Phase III/IIIb or definitive Phase II/III trial, does not contain a drug-containing intervention (it is a non-drug follow-up model comparison), and does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint was hospital contacts, and secondary endpoints included QoL and distress metrics.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for the Use of Radiation in the Prevention and Treatment of Heterotopic Ossification (HO). PMID 42357986 · Am J Clin Oncol · 2026-Jun-26 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning. PMID 42348666 · Curr Opin Hematol · 2026-Jun-26 The record is a journal article review article (publication_type: Journal Article) summarizing mechanistic and clinical data on factor XIa inhibitors. It is not an original result report of a Phase III/IIIb or Phase II/III randomized trial. The review mentions oncology (cancer-associated thrombosis) as a potential indication, but does not report results of an oncology trial with a time-to-event efficacy endpoint. It does not contain original Kaplan-Meier data, HR, or other time-to-event results for an oncology indication.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Para-Aortic Lymph Node Staging and Oncologic Outcomes in Locally Advanced Cervical Cancer: A Narrative Review. PMID 42449603 · Cancers (Basel) · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis. PMID 42442095 · Eur J Cancer · 2026-Jun-25 The record is a cross-sectional review/meta-analysis of multiple trials, not an original primary report of a single trial. Therefore, it is excluded.
S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32. PMID 42360727 · JNCI Cancer Spectr · 2026-Jun-25 The record describes a secondary/prognostic biomarker analysis within a large randomized trial (MA.32). While the trial itself may be a definitive Phase III study, the specific report provided does not explicitly state the trial phase, and its primary focus is not on evaluating a drug intervention's efficacy but on the prognostic value of CA 15-3. Therefore, it fails the 'drug intervention' and 'explicit phase' criteria for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials. PMID 42351343 · Arthritis Rheumatol · 2026-Jun-25 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Strengthening cancer prevention in european schools: a randomized controlled trial of digital interventions in adolescents: the SUNRISE program. PMID 42351094 · BMC Public Health · 2026-Jun-25 The record describes a protocol for a cluster-randomized controlled trial of a digital health intervention for cancer prevention in adolescents. It is not a report of a completed Phase II/III or Phase III/IIIb randomized trial in human malignant neoplasm patients with a drug intervention and a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of the established ASAS definition and preliminary proposed data-driven cut-offs for inflammatory and structural MRI lesions in the sacroiliac joints for eligibility of patients with nonradiographic axial spondyloarthritis in clinical trials. PMID 42350183 · Ann Rheum Dis · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A multicenter randomized controlled trial comparing metallic stents with 10- versus 14-mm diameter for distal biliary obstruction caused by unresectable pancreatic carcinoma. PMID 42349763 · Gastrointest Endosc · 2026-Jun-25 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. PMID 42349017 · Blood Adv · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials. PMID 42348366 · Diabetes Obes Metab · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study. PMID 42347868 · Clin Cancer Res · 2026-Jun-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment. PMID 42343061 · Eur J Clin Pharmacol · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. PMID 42341302 · N Engl J Med · 2026-Jun-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis. PMID 42341301 · N Engl J Med · 2026-Jun-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. PMID 42206582 · N Engl J Med · 2026-Jun-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Potassium-competitive acid blockers for erosive reflux disease and stress ulcer prophylaxis: a narrative review. PMID 42084149 · Pol Arch Intern Med · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade. PMID 41999744 · Cell · 2026-Jun-25 The record describes a secondary, exploratory biomarker analysis (gut microbiome and recurrence) from a Phase III randomized trial (CheckMate 915). While it reports on recurrence-free survival (a time-to-event endpoint) in a drug-intervention trial, it is not the primary or key secondary efficacy report of the original trial's results. The analysis is a subgroup/post-hoc biomarker study, not the formal report of the trial's primary or pre-specified secondary efficacy outcomes (e.g., overall survival or the primary comparison of nivolumab+ipilimumab vs nivolumab for recurrence-free survival). Therefore, it is excluded as not being an original formal-result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy. PMID 41849227 · Blood · 2026-Jun-25 The trial is a Phase III randomized trial in oncology patients (AML/MDS) with time-to-event endpoints. However, the intervention is for GVHD prophylaxis using immunosuppressive agents (ATG, cyclophosphamide) in the transplant setting, not as a primary anticancer drug therapy. Therefore, it does not meet the criterion of a drug-containing intervention for treating malignant neoplasm.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improving basal cell carcinoma subtype diagnosis with dermoscopy and reflectance confocal microscopy: a multicentre prospective study. PMID 41685950 · Clin Exp Dermatol · 2026-Jun-25 The record describes a prospective diagnostic accuracy study for noninvasive imaging of basal cell carcinoma subtypes, not a randomized drug trial. It lacks a drug intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and is not a Phase III or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial. PMID 42396282 · medRxiv · 2026-Jun-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ora visual navigation course™ mobility test results in two individuals with CEP290 LCA after intravitreal injection of antisense oligonucleotide. PMID 42343659 · Ophthalmic Genet · 2026-Jun-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. PMID 42343117 · Nat Med · 2026-Jun-24 The record is a retraction notice for a previously published trial. The abstract is empty, so no details about the study population (human), intervention (drug), or primary/time-to-event endpoints can be verified. Therefore, eligibility cannot be established.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study. PMID 42341325 · Blood Adv · 2026-Jun-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial. PMID 42340618 · Breast Cancer · 2026-Jun-24 The report is a quality-of-life analysis from a Phase III randomized trial with a drug intervention and time-to-event endpoint, but it does not present primary or key secondary time-to-event efficacy results (e.g., OS, PFS).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis in Breast Cancer Radiation Treatment. PMID 42431149 · Clin Breast Cancer · 2026-Jun-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials. PMID 42337097 · Pulm Ther · 2026-Jun-23 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management? PMID 42336749 · Eur Urol Focus · 2026-Jun-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Inhaled nitric oxide for reducing major adverse events requiring intensive life support in adults undergoing cardiac surgery with cardiopulmonary bypass: protocol for a phase III, double-blind, multicenter randomized controlled trial (NORISC Trial). PMID 42336097 · Nitric Oxide · 2026-Jun-23 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical translation of an immunomodulatory cell therapy that is designed to convert "cold" tumors to "hot": A phase 2B trial in 3L MSS/pMMR metastatic colorectal cancer. PMID 42335577 · Transl Oncol · 2026-Jun-23 The trial is a Phase 2B, single-arm study. It is not randomized and is not Phase III/IIIb or Phase II/III, which are required eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage Trial in Singapore (S-CATCH): A Phase 2b, Randomized, Double-blind, Placebo-Controlled Trial. PMID 42332280 · Neurocrit Care · 2026-Jun-23 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod. PMID 42242900 · J Neurol Neurosurg Psychiatry · 2026-Jun-23 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial. PMID 42033722 · JAMA · 2026-Jun-23 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. PMID 41949390 · Blood Adv · 2026-Jun-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical Efficacy of Modified San'ao Decoction and Erchen Decoction for Esophageal Dysphagia (Shi Bi) with Phlegm-Dampness and Blood Stasis Syndrome. PMID 42406624 · J Vis Exp · 2026-Jun-22 The record is a protocol for a randomized controlled trial with drug interventions (camrelizumab, anlotinib) in oncology. However, it is a protocol without final, peer-reviewed results reporting primary/key secondary time-to-event endpoints (OS, PFS, etc.). The abstract describes preliminary, short-term efficacy (ORR, DCR) and safety findings, but not Kaplan-Meier, HR, or other time-to-event data. The phase is not explicitly stated as Phase III/IIIb; the design is open-label and single-center, limiting definitiveness. Therefore, it does not meet all criteria for inclusion as a definitive Phase III RCT with time-to-event results.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Integration of lung tissue proteomics and genome-wide association data to identify lung cancer susceptibility proteins and potential drug targets. PMID 42396338 · medRxiv · 2026-Jun-22 The record describes a genomic/proteomic study identifying lung cancer susceptibility proteins and potential drug targets. It is not a clinical trial report and lacks the core elements of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -